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Histidines 107 and 109 in the glycine receptor (GlyR)
1 subunit have previously been identified as determi-
nants of the inhibitory zinc-binding site. Based on mod-
eling of the GlyR 1 subunit extracellular domain by
homology to the acetylcholine-binding protein crystal
structure, we hypothesized that inhibitory zinc is bound
within the vestibule lumen at subunit interfaces, where
it is ligated by His107 from one subunit and His109 from
an adjacent subunit. This was tested by co-expressing 1
subunits containing the H107A mutation with 1 sub-
units containing the H109A mutation. Although sensitiv-
ity to zinc inhibition is markedly reduced when either
mutation is individually incorporated into all five sub-
units, the GlyRs formed by the co-expression of H107A
mutant subunits with H109A mutant subunits exhibited
an inhibitory zinc sensitivity similar to that of the wild
type 1 homomeric GlyR. This constitutes strong evi-
dence that inhibitory zinc is coordinated at the inter-
face between adjacent 1 subunits. No evidence was
found for  subunit involvement in the coordination of
inhibitory zinc, indicating that a maximum of two zinc-
binding sites per 1 receptor is sufficient for maximal
zinc inhibition. Our data also show that two zinc-bind-
ing sites are sufficient for significant inhibition of 1
homomers. The binding of zinc at the interface between
adjacent 1 subunits could restrict intersubunit move-
ments, providing a feasible mechanism for the inhibi-
tion of channel activation by zinc.
Zinc is concentrated into round, clear presynaptic vesicles in
central nerve terminals and is released into the synaptic cleft
by nerve stimulation (1–3). During synaptic stimulation, zinc is
thought to reach a peak external concentration of more than
100 M (1, 3, 4). At such concentrations, zinc is potentially able
to modulate a wide variety of pre- and postsynaptic ion chan-
nels (5). Several lines of evidence suggest that the glycine
receptor chloride channel (GlyR),1 which mediates inhibitory
neurotransmission in the spinal cord and brainstem (6), may be
a physiological target for zinc modulation. First, zinc exerts
potent effects on the GlyR; low concentrations (0.01–10 M)
potentiate glycinergic currents by increasing the apparent gly-
cine affinity, whereas higher concentrations (10 M) inhibit
the current by reducing the apparent glycine affinity (7). Sec-
ond, an ultrastructural study has found evidence for zinc and
glycine co-localization in individual presynaptic terminals in
the spinal cord (8). Third, at glycinergic synapses onto intact
zebrafish hindbrain (Mauthner) neurons, zinc chelators de-
creased the amplitude, duration, and frequency of glycinergic
inhibitory postsynaptic currents, whereas zinc application had
the opposite effect (9).
The GlyR is a member of the ligand-gated ion channel (LGIC)
receptor family, which includes the nicotinic acetylcholine re-
ceptor cation channel (nAChR), the -aminobutyric acid type-A
and type-C receptor chloride channels (GABAAR and
GABACR), the serotonin receptor cation channel (5HT3R), and
a recently identified zinc-gated cation channel (10) as well as
invertebrate glutamate and histamine receptors (11). These
receptors are composed of five structurally similar subunits
arranged in a ring to form a central ion-conducting pore (12).
Adult GlyRs in vivo are composed of  and  subunits in a
3/2 stoichiometry (13). Although  subunits readily form
homomeric GlyRs in heterologous expression systems,  sub-
units form functional receptors only as heteromers with 
subunits. The molecular mechanisms of zinc inhibition and
potentiation have recently been investigated in several labora-
tories (7, 14–16). Although the molecular basis of potentiation
has so far proved elusive, a strong case has been advanced for
a candidate inhibitory site. Harvey et al. (15) showed that zinc
inhibition of the recombinant 1 GlyR was selectively abolished
by either reducing the pH or by pretreating receptors with a
histidine-specific modifying agent. Since both treatments effec-
tively reduce the ability of zinc to bind to histidine imidazole
rings, this implicated histidines in the coordination of inhibi-
tory zinc. Mutations of either His107 or His109 were subse-
quently shown to abolish zinc inhibition, strongly suggesting
that these residues coordinate zinc at its inhibitory site (15).
For a pair of histidine side chains to coordinate a zinc ion, the
-carbon atoms need to be within 13 Å of each other (17). Since
histidines 107 and 109 are separated by only one residue, it is
certainly feasible that this pair could coordinate zinc ions
within individual  subunits. Indeed, histidines with this spac-
ing occur in many structurally defined zinc-binding sites (17),
including carbonic anhydrase II (Protein Data Bank code
1CA2) (18), which contains the same HFH tripeptide as GlyR
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1 107–109, thereby providing a plausible model for zinc bind-
ing within individual GlyR 1 subunits (15). The recently re-
solved crystal structure of a soluble acetylcholine-binding pro-
tein (AChBP) from the snail, Lymnaea stagnalis, has provided
a structural model for the N-terminal ligand-binding domain of
LGICs (19). Modeling of the GlyR N-terminal domain, based on
AChBP, places His107 and His109 near the lumen of the channel
vestibule close to the axis of symmetry (20). In this position,
His107 and His109 from adjacent  subunits could be close
enough to coordinate zinc ions across the subunit interface, as
recently predicted by Laube et al. (21).
The aim of this study was to use a combination of homology
modeling based on the AChBP crystal structure, coupled with
functional analysis of GlyRs incorporating site-directed muta-
tions in putative zinc-binding regions, to provide insights into
the structure of the inhibitory zinc-binding site.
EXPERIMENTAL PROCEDURES
Mutagenesis and Expression of GlyR cDNAs—The human GlyR 1
and  subunit cDNAs were subcloned into the pCIS2 and pIRES2-
EGFP plasmid vectors (Clontech, Palo Alto, CA), respectively. Site-
directed mutagenesis was performed using the QuikChange mutagen-
esis kit (Stratagene, La Jolla, CA), and the successful incorporation of
mutations was confirmed by sequencing the clones. HEK293 cells were
transfected using a calcium phosphate precipitation protocol. When
co-transfecting the GlyR  and  subunits, their respective cDNAs were
combined in a ratio of 1:10 (22). After exposure to transfection solution
for 24 h, cells were washed twice using the culture medium and used for
recording over the following 24–72 h.
Electrophysiology—The cells were observed using a fluorescent mi-
croscope, and currents were measured using the whole cell patch clamp
configuration. Cells were perfused by a control solution that contained
140 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, 10
mM glucose, with the pH adjusted to 7.4 with NaOH. Patch pipettes
were fabricated from borosilicate hematocrit tubing (Vitrex, Modulohm,
Denmark) and heat-polished. Pipettes had a tip resistance of 1.5–3
megaohms when filled with the standard pipette solution, which con-
tained 145 mM CsCl, 2 mM CaCl2, 2 mM MgCl2, 10 mM HEPES, 10 mM
EGTA, with the pH adjusted to 7.4 with NaOH. After establishment of
the whole cell configuration, cells were voltage-clamped at40 mV, and
membrane currents were recorded using an Axopatch 1D amplifier and
pclamp6 software (Axon Instruments, Foster City, CA). The cells were
perfused by a parallel array of microtubular barrels through which
solutions were gravity-induced.
Because the  subunit can efficiently assemble into functional GlyRs
as either  homomers or  heteromers, it is necessary to confirm the
incorporation of  subunits into functional receptors. This was achieved
in two ways. First, green fluorescent protein expression was used to
identify cells expressing GlyR  subunit protein. Second, picrotoxin
sensitivity was used as a functional assay of the incorporation of 
subunits into heteromeric GlyRs (22). When co-expressed with  sub-
units in HEK293 cells, incorporation of  subunits increases the picro-
toxin IC50 from around 25 to 500 M in the presence of an EC50 glycine
concentration (23). In the present study, we measured the effect of 1 mM
picrotoxin on the magnitude of currents activated by an EC20 glycine
concentration, and cells were assumed to express  heteromeric GlyRs
if 1 mM picrotoxin inhibited the current by less than 50%.
Data Analysis—The empirical Hill equation, fitted by a nonlinear
least squares algorithm (Sigmaplot; Jandel Scientific, San Rafael, CA),
was used to calculate the EC50, the IC50, and the Hill coefficients (nH) of
excitatory and inhibitory dose-response curves. Statistical significance
was determined by a one-way analysis of variance using the Student-
Newman-Keuls post hoc test for unpaired data (Sigma Stat; Jandel
Scientific), with p  0.05 representing significance.
Molecular Modeling—Models of the extracellular region of the hu-
man GlyR 1 subunit were constructed by homology modeling, using
the crystal structure of AChBP from the snail Lymnaea stagnalis as a
template (Protein Data Bank entry 1I9B) (19). Sequence identity be-
tween LGICs and AChBP is only 15–24%, in the “twilight zone” for
effective alignment and homology modeling (24). To improve the reli-
ability of the alignment, we used ClustalW (25) to align AChBP with a
large number of Cys loop LGICs, particularly those that are the most
similar to AChBP, such as nAChRs, as described in Ref. 20. Secondary
structure predictions using the PHD prediction algorithm (26) assisted
the alignment in regions of particularly low homology, such as the
N-terminal -helix. Swiss-Model (27) was used to create independent
monomer models for each alignment tested. Loop regions that corre-
spond to gaps in the alignment were modeled by fitting structures from
a loop data base and are the least reliable sections of the models.
Acceptable monomer models were then assembled into pentamers using
AChBP as a scaffold. The assembled pentamer was energy-minimized
using INSIGHT II DISCOVER (Accelrys, San Diego, CA) to eliminate
any obvious problems such as steric clashes. Ramachandran plots and
Verify-3D scores (28) were used to assess the quality of each model. For
regions of a model that scored poorly, other possible alignments were
tested. Four different alignments were tested in the region in the
putative inhibitory zinc-binding region surrounding His107 and His109
(Fig. 1A). Excluding the inhibitory zinc-binding region, there are only
three residues that fall in the disallowed region of a Ramachandran
plot, Leu83 and His201, which are in loops corresponding with gaps in
the alignment, and Lys33, which corresponds to Arg23 in AChBP, which
also falls in the disallowed region. Total Verify-3D scores were above 64
for all models, which is quite acceptable for this type of model (28). With
a sliding window of 21 residues, there are no regions with a negative
score, but there are three regions that score below 0.2. These are the
N-terminal helix and the loop between the second and third -strands,
which are both likely to interact with residues 1–10, and the signature
Cys loop, which is likely to interact with the membrane domain. Since
our models do not include residues 1–10 or the membrane domain, they
cannot fully represent the native environment for the three regions
mentioned. Finally, a conserved N-glycosylation site at Asn38 is on the
surface of the model, consistent with it being glycosylated, and the
unique disulfide bond of GlyRs is present in our models.
RESULTS
Homology Modeling Indicates That His107 and His109 Face
the Vestibule Lumen—Based on earlier findings (14–16), we
started with the premise that His107 and His109 coordinate zinc
at the inhibitory site of 1 homomeric GlyRs. In an attempt to
understand the structural basis for zinc inhibition, we built
models of the GlyR 1 subunit extracellular region, based on
homology to AChBP, as described in Cromer et al. (20), using
the alignments shown in Fig. 1A. Histidines 107 and 109 of the
GlyR 1 subunit fall within a region from Lys
104 to Asn115,
which we have termed the “inhibitory zinc-binding region” (Fig.
1A), that shares little homology with AChBP but is flanked by
sequences with strong homology. These flanking sequences
anchor the zinc-binding region within the model such that it
faces the lumen of the extracellular vestibule, near the axis of
symmetry and subunit interfaces (Fig. 1B; see also Ref. 20).
Although the detailed structure of the zinc-binding region can-
not be reliably predicted, its location near the axis of symmetry
immediately raises the possibility that His107 and His109 from
adjacent subunits could be close enough to coordinate zinc in an
intersubunit site, as recently suggested by others (21). On the
other hand, the possibility of an intrasubunit site with zinc
coordinated by His107 and His109 from the same subunit, as
proposed by Harvey et al. (15), remains also feasible. Conse-
quently, our first aim, experimentally, was to discriminate
between these alternative models for inhibitory zinc binding.
His107 and His109 from Adjacent Subunits Form the Inhibi-
tory Zinc-binding Site—To discriminate experimentally be-
tween intrasubunit and intersubunit models for the inhibitory
zinc-binding site, we examined the zinc sensitivity of GlyRs
formed from co-expression of H107A and H109A subunits, each
of which individually shows reduced zinc sensitivity. The ra-
tionale was that if the inhibitory zinc-binding site is formed
within a subunit, then these mixed receptors should be zinc-
insensitive, since each subunit contains only one of the two
required histidine residues. Therefore, if the resultant recom-
binant receptors possess a high affinity zinc inhibitory site,
then this site must be formed at the interface between sub-
units. It is important to note that this approach cannot address
the question of whether zinc can also be coordinated within
individual subunits. Hence, in all our experiments, it is neces-
sary to eliminate at least one histidine (His107 or His109) per
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subunit to ensure that this does not confound the interpreta-
tion of our results.
The mean glycine EC50, nH, and Imax values for the WT and
all mutant GlyRs employed in this study are shown in Table I.
As demonstrated previously, the WT GlyR is highly sensitive
to zinc inhibition. As expected from previous studies employing
mutations at these positions (7, 15, 16, 29), none of these
mutations had dramatic effects on the glycine EC50, nH, or Imax
values. The inhibitory zinc dose responses for the H107A GlyR,
the H109A GlyR, the double mutant H107A,H109A GlyR, and the
co-expressed (H107A  H109A) GlyR were measured in the
presence of an EC20 glycine concentration. Zinc inhibition was
quantitated by measuring the steady-state level of the current
following application of zinc and expressing this as a fraction of
the peak magnitude of the zinc-potentiated current (14). Sam-
ple responses to increasing concentrations of zinc for each of
these receptor constructs are shown in Fig. 2A. Averaged zinc
inhibitory dose responses are plotted in Fig. 2B, and the mean
zinc IC50 and nH values for these and all other recombinant
constructs examined in this study are summarized in Table I.
The H107A mutation reduced the inhibitory potency by a factor
of 15, whereas the H109A mutation almost entirely abolished
zinc inhibition (Table I), consistent with earlier results (15) and
the proposed role of these residues in zinc coordination. The
difference in the magnitude of the effect of the two mutations
indicates that the zinc coordination is not perfectly symmetric,
consistent with the probable involvement of other residues (16).
As expected, the double mutant H107A,H109A GlyR was also
insensitive to zinc inhibition (Fig. 2A).
When the two single mutant H107A  H109A subunits were
co-expressed, high sensitivity zinc inhibition was observed (Fig.
2, A and B). The zinc sensitivity (21  5 M; Table I) was not
significantly different from that of the WT GlyR (16  8 M),
consistent with it being due to the same zinc-binding site. This
inhibition could not have been mediated by zinc ions binding
within individual subunits, since each subunit contained only
one of the two required histidine residues. Therefore, it must
have been due to intersubunit coordination of zinc ions by
His107 and His109 from different subunits, supporting the hy-
pothesis of an intersubunit zinc site and the positioning of the
inhibitory zinc-binding region in our initial model (Fig. 1). The
two coordinating histidines almost certainly come from adja-
cent subunits, since the constraints imposed on the model by
the conserved anchor points make it virtually impossible for
His107 and His109 from nonadjacent subunits to get close
enough to coordinate zinc across the vestibule lumen. The fact
that the inhibition seen with the mixed H107A  H109A GlyRs
TABLE I
Functional properties of WT and mutant GlyRs
Transfected subunits
Glycine Zinc
EC50 nH Imax n IC50 nH n
M nA
WT 22  5 3.1  0.3 2.1  1.0 7 16  8 M 0.6  0.1 4
H107A 26  3 1.2  0.1 1.4  0.7 3 247  43 M 1.1  0.3 6
H109A 51  6 2.0  0.5 3.9  1.9 3 1 mM NA
a 5
H107A,H109A 60  4 2.0  0.3 6.1  0.7 3 1 mM NA 8
H107A  H109A 40  1 1.8  0.1 2.7  1.0 5 21  5 M 0.6  0.2 6
T112V 43  6 1.3  0.2 2.2  0.7 5 1 mM NA 3
H107A,T112V 15  4 1.1  0.1 1.5  0.6 6 1 mM NA 5
H109A,T112V 15  2 0.8  0.1 0.7  0.1 6 1 mM NA 5
H107A  T112V 19  2 1.1  0.1 3.6  1.6 3 1 mM NA 3
H109A  T112V 19  4 1.1  0.3 1.4  0.5 3 1 mM NA 3
H107A  H109A,T112V 48  13 1.0  0.3 4.8  2.1 4 1 mM NA 3
WT  WT 25  4 2.7  0.7 2.6  0.7 8 16  5 M 0.6  0.1 5
H109A  WT 44  2 2.2  0.2 3.7  0.9 3 1 mM NA 3
H107A,H109A  N130H 60  6 2.6  0.6 2.6  0.6 5 1 mM NA 4
WT  H132A 41  1 3.6  0.1 2.6  1.0 3 11  4 M 0.8  0.3 3
a NA, not applicable.
FIG. 1. Model of the 1 GlyR. A, alignment used for homology
modeling of 1 GlyR based on AChBP structure. The boxes show iden-
tical residues (open) and residues conserved throughout LGIC super-
family (shaded). Secondary structure elements of AChBP structure are
shown, with -strands in orange and the -helix in green. The open
green box shows the predicted -helix using PHD (26). The putative
inhibitory zinc-binding region is shown in blue, with His107 and His109
in pink. Alternative sequence alignments of AChBP to this region are
shown as models A–D (in parentheses). B, backbone ribbon representa-
tion of model homopentameric 1 GlyR (built using alignment C above)
viewed along the axis of symmetry from the synaptic cleft side. The
colors indicate each subunit. Dotted lines mark the subunit interfaces,
with plus and minus signs indicating the subunit faces that contribute
to the interface. The putative inhibitory zinc-binding region is shown in
blue, with His107 and His109 side chains shown as bonds in pink. The
arrow shows the point of view used in Fig. 4.
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was not seen in either of the single mutants alone indicates
that His107 and His109 each occupy a specific subunit “face”
(either or; see Fig. 1) and are not flexible to coordinate zinc
at either face. Therefore, an intersubunit zinc site can only
occur at one of the two possible / interfaces, either H107A/
H109A or H109A/H107A. This limits the number of inhibitory
zinc sites in a pentamer of mixed H107A  H109A subunits to
a maximum of two (Table II), demonstrating that two such sites
are sufficient for inhibition by zinc. The relatively low nH for
zinc inhibition in WT GlyRs and our finding that it is un-
changed in the mixed H107A  H109A GlyRs support the view
that one or two bound zinc molecules may be sufficient for
maximal zinc inhibition in the WT GlyR (Table II).
Zinc inhibition of the mixed H107A  H109A GlyRs was
incomplete (Fig. 1, A and B), however, inhibiting a maximum of
55  5% (n  6) of the glycine-activated current. In contrast, a
saturating (1 mM) zinc concentration inhibits the WT GlyR
current by 100% (Fig. 1B; see also Refs. 7 and 14). The reduced
extent of zinc inhibition is not unexpected, given that each
receptor in the mixed population of mutant receptors contains
zero, one, or two zinc-binding sites, relative to five sites in WT
receptors. Assuming the H109A and H107A subunits recombine
in a random binomial manner to form pentameric GlyRs, 6.2%
of recombinant GlyRs should have no zinc-binding sites, 62.4%
should have one inhibitory zinc-binding site, and 31.2% should
contain two inhibitory zinc-binding sites per receptor (Table II).
The 55% overall inhibition could be explained by GlyRs with
two zinc sites being inhibited completely and those with one
site being partially inhibited. Although this is a reasonable
explanation, random recombination cannot be assumed, and
other explanations are possible. In summary, the data above
show that an intersubunit zinc-binding site can account for the
zinc inhibition observed in WT 1 homomeric GlyRs but do not
rule out an additional role for intrasubunit binding.
Possible Involvement of Thr112 in Zinc Coordination—Laube
et al. (16) showed that a T112A mutation abolished inhibition
by zinc and proposed that Thr112 is also involved in the coor-
dination of zinc at its inhibitory site. If Thr112 directly coordi-
nates zinc at an intersubunit inhibitory site, then co-expression
of either the H107A or H109A subunits with the T112A subunit
should be able to restore zinc sensitivity, as observed for the
two histidines above. To test this concept, we made the more
conservative T112V mutation, which simply replaces the hy-
droxyl group of the threonine with a methyl group. As with the
T112A mutation (16), the T112V mutation had little effect on
glycine sensitivity but completely eliminated sensitivity to zinc
inhibition (Table I). As expected, the double mutant
H107A,T112V and H109A,T112V GlyRs were also insensitive to
zinc inhibition (Table I). However, these experiments provide
no information as to whether T112V caused a nonspecific struc-
tural disruption to the zinc coordination scaffold or whether it
FIG. 2. Zinc inhibition of  homomeric GlyRs. A, examples of zinc
inhibitory dose responses are shown for the H107A GlyR (top left panel),
the H109A GlyR (top right), the double mutant H107A,H109A GlyR (bot-
tom left), and GlyRs comprising both H107A and H109A subunits (bot-
tom right). EC20 glycine applications are indicated by the thin lines, and
periods of zinc application are shown by the thick lines. Zinc concentra-
tions applied in each panel are indicated. In each case, progressively
increasing the zinc concentration caused an increased degree of block.
The horizontal scale bar represents 5 s and applies to all panels. The
vertical scale bar represents 0.8 nA (top left panel), 1.2 nA (top right),
1.3 nA (bottom left), and 0.2 nA (bottom right). B, averaged dose re-
sponses for the WT GlyR (filled circles), the H107A GlyR (filled trian-
gles), and the H107A  H109A GlyR (open triangles). Error bars, S.E.;
curves, Hill equation fits to averaged data. Averaged parameters of best
fit to individual dose responses are given in Table I.
TABLE II
Possible subunit arrangements resulting from the
recombinant expression of H107A and H109A subunits
The probability of each combination, together with the number of
intersubunit zinc-binding sites, is also shown. Net probability of 0 zinc
sites: 6.2%, 1 zinc site: 62.4%, 2 zinc sites: 31.2%.
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directly participated in zinc coordination. To test the possibility
of direct coordination, we co-expressed H107A  T112V, H109A
 T112V, or H107A  H109A,T112V subunits. As summarized in
Table I, none of these mixed receptors was significantly inhib-
ited by 1 mM zinc. The fact that co-expression did not restore
zinc sensitivity provides no evidence to support a direct role for
Thr112 in coordinating zinc. Although T112V mutant subunits
contain both His107 and His109, the T112V mutation eliminates
functional inhibitory zinc-binding sites at both faces of the
subunit, by either 1) disrupting the structure of the zinc-bind-
ing region, either directly or allosterically, or 2) precluding the
formation of GlyRs containing both mutant subunits. These
data do not, however, rule out a direct role for Thr112 in zinc
coordination, since it could have both a coordinating and a
more structural role.
Zinc Coordination by  Heteromeric GlyRs—To further
characterize the inhibitory zinc-binding site, we examined its
properties in the 1 heteromeric GlyR. As stated under “Ex-
perimental Procedures,” the incorporation of  subunits into 
heteromers was confirmed for each cell by measuring the per-
centage inhibition of the EC20 glycine current that was inhib-
ited by 1 mM picrotoxin. If the picrotoxin inhibited this current
by no more than 50% (c.f. Refs. 22, 23, and 30), it was assumed
that all recombinant receptors in that cell contained 3 and 2
subunits (13). Since the arrangement of the  and  subunits
around the pentamer has not been determined, we considered
the possibility that the  subunits may be located either side-
by-side or separated by an  subunit (Table III).
Examples of the effects of zinc on heteromeric WTWT GlyRs
are shown in Fig. 3A, and the averaged zinc dose response is
plotted in Fig. 3B. The mean zinc IC50 and nH values are
summarized in Table I. As previously demonstrated (7), the
zinc inhibitory potency of these receptors is similar to that of
the homomeric WT GlyR (Table I). The  subunit contains a
histidine at position 132, which is homologous with His109 in
the  subunit. However, it contains an asparagine (Asn130) at
the position homologous with His107. Since asparagine residues
are not known to coordinate zinc ions (17), it is feasible that
only the  subunit His132, located at the plus side of the -
subunit interface, may coordinate zinc ions. Given this possi-
bly, heteromeric WTWT GlyRs may contain a maximum of
three intersubunit zinc coordination sites as shown in Table III
(top row).
Several approaches were employed to determine whether -
subunit interfaces could coordinate zinc ions. First, we incor-
porated the  subunit H132A mutation to determine its effect
on zinc inhibitory potency. The resultant WTH132A GlyRs
contain either one or two - subunit interfaces, depending on
the subunit arrangement (Table III, row 2). As shown in Fig. 3,
A and B, and summarized in Table I, these receptors were
highly sensitive to zinc inhibition, with a mean IC50 of 11  4
M (n  3). Thus, heteromeric GlyRs containing a maximum of
two zinc inhibitory sites can be maximally inhibited by zinc.
TABLE III
Possible arrangements of intersubunit zinc binding sites resulting
from the recombinant expression of WT and mutant  and  subunits
* In this analysis, a zinc site is presumed to exist across any type of
subunit interface, provided that two histidine residues are present on
both sides of the interface at positions homologous with His107 and
His109 of the 1 subunit.
FIG. 3. Effects of zinc on  heteromeric GlyRs. A, examples of
zinc dose responses are shown for the WTWT GlyR (top left), the
WTH132A GlyR (top right), the H109AWT GlyR (bottom left), and the
H107A,H109AN130H GlyR (bottom right). Zinc concentrations applied in
each panel are indicated. In each case, progressively increasing the zinc
concentration caused an increased degree of block. The horizontal scale
bar indicates 5 s and applies to all panels. The vertical scale bar
represents 0.5 nA (top left panel), 0.4 nA (top right), 1.1 nA (bottom left),
and 1 nA (bottom right). B, averaged dose responses for the WTWT
GlyR (filled circles) and the WTH132A GlyR (filled triangles). Error
bars, S.E.; curves, Hill equation fits to averaged data. Averaged param-
eters of best fit to individual dose responses are given in Table I.
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These results provide no evidence for a contribution of putative
- interface zinc sites to zinc-induced inhibition of glycine
currents.
The second approach involved removing all - subunit zinc
sites via the H109A mutation. The resultant heteromeric
GlyRs would then have contained either one or two - inter-
face sites, depending on the subunit arrangement (Table III,
row 3). Since the resultant H109AWT GlyRs receptors were
completely insensitive to zinc inhibition (Fig. 3, A and B, and
Table I), whereas heteromers containing a similar number of
sites at - subunit interfaces were highly zinc-sensitive, it is
concluded that inhibitory zinc-binding sites are not formed at
- interfaces or at - interfaces. In a final experiment, we
investigated the zinc sensitivity of the H107A,H109AN130H
GlyR. Although experiments described above suggest that this
construct would not be zinc-sensitive, it was considered worth
trying, since a high zinc sensitivity would have been evidence
for a side-by-side arrangement of  subunits (Table III, row 4).
As anticipated, however, the construct was completely insensi-
tive to zinc inhibition (Fig. 3, A and B, and Table I). In sum-
mary, we found no evidence for a direct contribution of the 
subunit to inhibitory zinc-binding sites.
Possible Conformations of the Inhibitory Zinc-binding Re-
gion—In our initial model of the GlyR extracellular domain,
the inhibitory zinc-binding region is anchored by the flanking
sequences, which have strong homology to AChBP, but the
zinc-binding region itself is not reliably modeled because of
weak homology and the inclusion of 3 extra residues relative to
AChBP. It is now worth reconsidering models of possible con-
formations of this region in terms of how well they fit our
experimental evidence for intersubunit inhibitory zinc-binding
sites. Since  subunits do not appear to contribute directly to
these sites, we have restricted the modeling to 1 homopentam-
ers. To sample possible conformations of this region, we built a
series of models (A–D), each based on a different alignment in
the 104–115 region as shown in Fig. 1A. To maintain as much of
the AChBP secondary structure as possible, the gaps in the
alignment with the zinc-binding region were placed at either end
of the short -strand in AChBP. Each model was built independ-
ently from scratch, as described under “Experimental Proce-
dures.” Models were then assessed in terms of how well they fit
the experimental data and their quality as protein structures.
We have shown here that intersubunit coordination of zinc
by His107 and His109 can account for essentially all the proper-
ties of zinc inhibition. Therefore, we examined each of the
models to see whether they were consistent with such coordi-
nation. The constraints of zinc coordination by histidine imid-
azole nitrogens (17) place the zinc less than 6 Å from the
histidine -carbon atom. Consequently, the -carbon atoms of
two histidines coordinating the same zinc must be within 12 Å
of each other. For tetrahedral geometry, the most common
coordination geometry for zinc, the -carbons must be within
10 Å of each other. The intersubunit distance between -car-
bons of His107 and His109 is 10 Å for model C (making tetra-
hedral coordination possible), 12 Å for models A and D (sug-
gesting that coordination is possible), but 15 Å for model B
(essentially ruling this model out as a viable model for an
intersubunit zinc site). Given appropriate distance constraints,
side chain orientation and surrounding structure also deter-
mine the feasibility of zinc coordination. To examine the feasi-
bility of zinc binding in each model, we tested whether a rea-
sonable zinc site could be produced by manually adjusting the
side chain position of the two histidines within allowed rotam-
ers while keeping the backbone fixed. Model C was able to most
closely approach ideal tetrahedral geometry, but models A and
D could also approach a reasonable zinc-binding site. The best
positions achieved are shown in Fig. 4, together with a possible
location for bound zinc in models A, C, and D. Interestingly, for
models C and D, coordination by His109 and His107 was from
the minus and plus faces, respectively, whereas this was re-
versed in model A.
FIG. 4. Close-up view of putative inhibitory zinc-binding site
in models A, B, C, and D, viewed from within the vestibule lumen
as indicated by the arrow in Fig. 1. Only two subunits are shown for
clarity. Side chains of His107 and His109 from the plus face (right) and
His107, His109, Glu110, and Thr112 from the minus face (left) are shown as
bonds, with standard coloring according to atom. Pink spheres indicate
possible locations for bound zinc.
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We have also shown that Thr112 appears to have a structural
role in the zinc-biding site but may have an additional direct
role in zinc coordination. None of our models are consistent
with Thr112 directly coordinating zinc, together with His107 and
His109. Models C and D do, however, indicate that the side
chain hydroxyl, which is removed in both the T112V (this
study) and T112A (16) mutants that abolish zinc inhibition,
could form hydrogen bonds with other parts of the structure.
These potential hydrogen bonds could be determinants of a
structural role for Thr112. Although we have not tested its role
here, an E110A mutation has been shown to reduce sensitivity
to zinc inhibition by 16-fold (16), indicating that it could be a
third ligand for coordinating zinc. Of the models that could
coordinate zinc by the two histidines, only in models C and D is
Glu110 close enough to play a role in coordinating zinc, either
directly or through a water molecule. Ramachandran plots and
Verify-3D scoring both measure how well a model structure fits
the characteristics of real protein structures, independent of
the modeling process. Ramachandran plots for our models re-
veal that the inhibitory zinc-binding region of model C has no
residues in the disallowed regions, whereas the other models
have one or two residues each in the disallowed regions. Model
C also gave a markedly higher Verify-3D score than the other
three models, indicating that it can be objectively considered
the most reasonable protein structure of the four models. In
summary, whereas models A and D are possible models of an
intersubunit inhibitory zinc-binding site, model C is our pre-
ferred working model.
DISCUSSION
Mechanism of Zinc Inhibition—This study shows that inhib-
itory zinc-binding sites are formed at GlyR 1 subunit inter-
faces, where zinc is coordinated by His107 and His109 residues
from adjacent subunits. We cannot rule out the possibility that
His107 and His109 are also able to coordinate zinc within the
same subunit, but an intersubunit site is able to account for
essentially all of the inhibitory properties of zinc in WT recep-
tors. Although zinc bound within proteins is normally coordi-
nated by at least three side chains, coordination by only these
two histidines may be sufficient to explain the relatively low
binding affinity of the inhibitory zinc-binding site. Similar low
micromolar affinity is seen in a mutant carbonic anhydrase
that retains two histidine ligands and probably a water (18).
Thr112 appears to have a significant structural role in this
region, but we cannot rule out the possibility that it may also
contribute to the coordination of zinc. Glu110 has also been
shown to be important for zinc inhibition (16) and could be
involved in coordinating zinc, either directly or through a water
molecule, but this was not tested here. The present study also
shows that functional zinc inhibitory sites are not formed at the
interfaces between  and  subunits or between  subunits.
Furthermore, since inhibitory zinc sites are formed only at the
interface between  subunits, a maximum of two occupied sites
is sufficient to completely inhibit the  heteromeric GlyR. A
maximum of two occupied sites is also sufficient to give signif-
icant, possibly complete, inhibition of the  homomeric GlyR.
The potency of zinc inhibition is increased as the glycine
concentration is reduced (7). In addition, zinc inhibition
reaches a steady-state level much faster in the absence of
glycine (14). A single channel study found that high (50 M)
zinc concentrations reduced 1 GlyR open probability by reduc-
ing mean channel open time and the relative abundance of long
channel bursts (16). It concluded that zinc increased the rate at
which the channel exits from the open state. Together, these
results suggest that glycine-induced activation is accompanied
by a structural change at the zinc inhibitory site and that zinc
acts to prevent this by stabilizing the closed conformation.
Based on our models, the inhibitory zinc-binding site is located
in close proximity to the agonist-binding site, and allosteric
interaction between the two could occur via relatively minor
local movements. Alternatively, since both these sites are at
subunit interfaces, they could interact via global movements of
subunits relative to one another. Consistent with this idea of
intersubunit movements, our models place Asp80, which has
been implicated in the potentiating zinc-binding site, at the
subunit interface on the outside of the pentamer. Although
this position is quite distant from the inhibitory zinc-binding
site, mutations of His109 affect zinc potentiation as well as
inhibition (15).
A model of receptor activation involving global intersubunit
movements has been proposed to account for a large body of
functional data obtained mainly from the nAChR (reviewed in
Refs. 31 and 32). This idea is also supported by recent struc-
tural evidence (33). An essential feature of this model is that
the largest displacements occur at the subunit interfaces. The
GlyR inhibitory zinc-binding site is located in an ideal position
to hinder these movements by locking adjacent subunits into a
fixed, closed position.
Zinc Sites in Other LGICs—Although zinc affects most LGIC
members (10, 34–37), to date putative zinc-binding sites have
been identified only in the GABAAR and in the GABACR. In the
GABAAR 5 subunit, zinc sensitivity is reduced by a H195D
mutation in the extracellular domain, immediately preceding
-strand 9, close to the membrane domain (38). In the GABAAR
 subunits, zinc sensitivity is reduced by mutating a histidine
in the second transmembrane domain (39, 40) or at the position
homologous to His109 in the GlyR 1 subunit (41). This latter
observation is the only evidence so far that the GlyR zinc
inhibitory site characterized in the present study may also be
functional in other LGIC members. However, it is of interest to
note that the recently identified zinc-activated cation channel
(10) contains aspartic acid residues at positions homologous to
107 and 110 in the GlyR 1 subunit, which could contribute to
a channel-activating zinc site. In GABACR 1 homomers, zinc
inhibition is abolished by mutating a histidine residue at the
subunit interface, close to the ligand-binding site (42). A recent
paper has identified an inhibitory zinc-binding site at the in-
terface between 1 and 3 subunits of the GABAAR, on the
outside of the extracellular domain close to the membrane (43),
a site that is quite distinct from the GlyR site characterized
here. Finally, there is strong structural and functional evidence
for a potentiating calcium binding site at the interface between
adjacent nAChR 7 subunits (44). In contrast with the present
study, the high affinity site is proposed to be associated with
the channel open state. Intersubunit binding sites appear to be
emerging as a common means for modulation of LGICs by
divalent cations, although the location of the site may vary.
There is some sense to this, given the intersubunit location of
agonist binding sites and the evidence for intersubunit move-
ment upon agonist binding (33).
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